Clinical Evaluation of Microbicide Formulations

Overview

Journal Antiviral Res

Publisher Elsevier

Date 2010 Nov 27

PMID 21109067

Citations 17

Authors

Kathleen M Morrow

Craig Hendrix

Affiliations

Soon will be listed here.

Abstract

The clinical evaluation of microbicide formulations presents variable and interacting challenges. Specific domains of acceptability, pharmacokinetics, and toxicity interact with each other to potentially inhibit or enhance a microbicide's efficacy. Each of these is further influenced by application and use parameters in the relative presence (or absence) of vaginal and/or seminal fluids, ultimately impacting effectiveness. Historically, acceptability of formulation and use parameters, and their concomitant behavioral influences, have been considered separately from pharmacokinetics and toxicity. While independent evaluation of these elements is necessary in some respects, we must acknowledge that this approach is not sufficient for the successful development of microbicides. Each needs to be considered in an integrated clinical evaluation strategy. This article presents the rationale for such an approach. This article forms part of a special supplement covering two presentations on clinical evaluation of microbicides from the symposium on "Recent Trends in Microbicide Formulations" held on 25 and 26 January 2010, Arlington, VA.

Citing Articles

Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials.

Hawley I, Song M, Scheckter R, McClure T, Piper J, Chen B AIDS Res Hum Retroviruses. 2021; 38(4):313-326.

PMID: 34969254 PMC: 9048173. DOI: 10.1089/AID.2021.0077.

Designing and developing suppository formulations for anti-HIV drug delivery.

Ham A, Buckheit Jr R Ther Deliv. 2017; 8(9):805-817.

PMID: 28825395 PMC: 6123880. DOI: 10.4155/tde-2017-0056.

User input in iterative design for prevention product development: leveraging interdisciplinary methods to optimize effectiveness.

Guthrie K, Rosen R, Vargas S, Guillen M, Steger A, Getz M Drug Deliv Transl Res. 2017; 7(5):761-770.

PMID: 28653286 PMC: 6103777. DOI: 10.1007/s13346-017-0397-0.

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.

Nelson A, Zhang X, Ganapathi U, Szekely Z, Flexner C, Owen A J Control Release. 2015; 219:669-680.

PMID: 26315816 PMC: 4879940. DOI: 10.1016/j.jconrel.2015.08.042.

Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.

Rosen R, Berg J, Vargas S, Senocak N, Shaw J, Buckheit Jr R Contraception. 2015; 92(6):596-601.

PMID: 26276246 PMC: 4664151. DOI: 10.1016/j.contraception.2015.08.007.

References

Hendrix C, Cao Y, Fuchs E . Topical microbicides to prevent HIV: clinical drug development challenges. Annu Rev Pharmacol Toxicol. 2008; 49:349-75. DOI: 10.1146/annurev.pharmtox.48.113006.094906. View

Dutta S, Joglekar N, Joshi S, Steven J . Experience of conducting a phase I safety & acceptability clinical trial of a candidate vaginal microbicide & lessons learned. Indian J Med Res. 2008; 128(2):212-3. View

Malcolm R, Edwards K, Kiser P, Romano J, Smith T . Advances in microbicide vaginal rings. Antiviral Res. 2010; 88 Suppl 1:S30-9. DOI: 10.1016/j.antiviral.2010.09.003. View

Szeri A, Park S, Verguet S, Weiss A, Katz D . A model of transluminal flow of an anti-HIV microbicide vehicle: Combined elastic squeezing and gravitational sliding. Phys Fluids (1994). 2009; 20(8):83101. PMC: 2698280. DOI: 10.1063/1.2973188. View

Coly A, Gorbach P . Microbicide acceptability research: recent findings and evolution across phases of product development. Curr Opin HIV AIDS. 2009; 3(5):581-6. DOI: 10.1097/COH.0b013e32830aba00. View

Mantell J, Myer L, Carballo-Dieguez A, Stein Z, Ramjee G, Morar N . Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2004; 60(2):319-30. DOI: 10.1016/j.socscimed.2004.05.011. View

Mauck C, Weiner D, Ballagh S, Creinin M, Archer D, Schwartz J . Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study. Contraception. 2004; 70(1):77-83. PMC: 2861169. DOI: 10.1016/j.contraception.2004.02.016. View

Hardy E, Jimenez A, de Padua K, Zaneveld L . Women's preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging. Contraception. 1998; 58(4):245-9. DOI: 10.1016/s0010-7824(98)00104-8. View

Morrow K, Fava J, Rosen R, Vargas S, Barroso C, Christensen A . Willingness to use microbicides is affected by the importance of product characteristics, use parameters, and protective properties. J Acquir Immune Defic Syndr. 2007; 45(1):93-101. PMC: 2628545. DOI: 10.1097/QAI.0b013e3180415ded. View

10.

Ramjee G, Morar N, Braunstein S, Friedland B, Jones H, van de Wijgert J . Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS Res Ther. 2007; 4:20. PMC: 2089066. DOI: 10.1186/1742-6405-4-20. View

11.

Bentley M, Morrow K, Fullem A, Chesney M, Horton S, Rosenberg Z . Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect. 2000; 32(4):184-8. View

12.

Vandebosch A, Goetghebeur E, Ramjee G, Alary M, Ettiegne-Traore V, Chandeying V . Acceptability of COL-1492, a vaginal gel, among sex workers in one Asian and three African cities. Sex Transm Infect. 2004; 80(3):241-3. PMC: 1744842. DOI: 10.1136/sti.2003.005934. View

13.

Tanner A, Zimet G, Fortenberry J, Reece M, Graham C, Murray M . Young women's use of a vaginal microbicide surrogate: the role of individual and contextual factors in acceptability and sexual pleasure. J Sex Res. 2008; 46(1):15-23. DOI: 10.1080/00224490802398407. View

14.

Talameh J, Rezk N, Kashuba A . Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 878(1):92-6. PMC: 2852126. DOI: 10.1016/j.jchromb.2009.11.015. View

15.

Whaley K, Hanes J, Shattock R, Cone R, Friend D . Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res. 2010; 88 Suppl 1:S55-66. DOI: 10.1016/j.antiviral.2010.09.006. View

16.

Lai B, Xie Y, Lavine M, Szeri A, Owen D, Katz D . Dilution of microbicide gels with vaginal fluid and semen simulants: effect on rheological properties and coating flow. J Pharm Sci. 2007; 97(2):1030-8. DOI: 10.1002/jps.21132. View

17.

Weeks M, Mosack K, Abbott M, Novick Sylla L, Valdes B, Prince M . Microbicide acceptability among high-risk urban U.S. women: experiences and perceptions of sexually transmitted HIV prevention. Sex Transm Dis. 2004; 31(11):682-90. PMC: 1567977. DOI: 10.1097/01.olq.0000143113.04524.a5. View

18.

Zubowicz E, Oakes J, Short M, Perfect M, Succop P, Rosenthal S . Adolescents' descriptions of the physical characteristics of microbicide surrogates and experiences of use. J Womens Health (Larchmt). 2006; 15(8):952-61. DOI: 10.1089/jwh.2006.15.952. View

19.

Morrow K, Fava J, Rosen R, Christensen A, Vargas S, Barroso C . Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type. Health Psychol. 2007; 26(6):777-86. PMC: 2628547. DOI: 10.1037/0278-6133.26.6.777. View

20.

Morrow K, Underhill K, Berg J, Vargas S, Rosen R, Katz D . User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides. Arch Sex Behav. 2014; 43(7):1459-67. PMC: 4327860. DOI: 10.1007/s10508-013-0235-5. View